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Dysregulated endoplasmic reticulum stress and phos-
phorylation of eukaryotic translation initiation factor 2a
(eIF2a) are associated with pancreatic b-cell failure and
diabetes. Here, we report the ﬁrst homozygous mutation
in the PPP1R15B gene (also known as constitutive re-
pressor of eIF2a phosphorylation [CReP]) encoding the
regulatory subunit of an eIF2a-speciﬁc phosphatase in
two siblings affected by a novel syndrome of diabetes
of youth with short stature, intellectual disability, and mi-
crocephaly. The R658C mutation in PPP1R15B affects
a conserved amino acid within the domain important for
protein phosphatase 1 (PP1) binding. The R658C mutation
decreases PP1 binding and eIF2a dephosphorylation and
results in b-cell apoptosis. Our ﬁndings support the con-
cept that dysregulated eIF2a phosphorylation, whether
decreased by mutation of the kinase (EIF2AK3) in Wolcott-
Rallison syndrome or increased by mutation of the phos-
phatase (PPP1R15B), is deleterious to b-cells and other
secretory tissues, resulting in diabetes associated with
multisystem abnormalities.
The molecular mechanisms contributing to pancreatic
b-cell dysfunction and apoptosis in diabetes remain
poorly understood. Accumulating evidence suggests that
endoplasmic reticulum (ER) stress and aspects of the re-
sponse to it contribute to b-cell failure both in type 1 and
type 2 diabetes (1–6). ER stress is deﬁned as an imbalance
between unfolded protein load in the ER and the organelle’s
functional capacity. This activates an ER stress response,
also known as the unfolded protein response (UPR), which
reduces protein load and increases ER folding capacity. The
UPR is an adaptive response, particularly important for the
survival of cells with a high secretory capacity such as pan-
creatic b-cells. The UPR is triggered by the activation of
ER transmembrane proteins that sense the misfolded pro-
tein accumulation in the ER lumen and transduce the signal
to the cytoplasm. One of the canonical ER stress trans-
ducers is protein kinase R-like endoplasmic reticulum ki-
nase (PERK, encoded by EIF2AK3). PERK phosphorylates
the eukaryotic translation initiation factor 2a (eIF2a) and
attenuates protein translation to lessen the burden of the
stressed ER (1,7). The effector pathway downstream of
PERK is tightly regulated by eIF2a dephosphorylation car-
ried out by a holophosphatase complex consisting of a com-
mon catalytic subunit, protein phosphatase 1 (PP1), and
a substrate-speciﬁc regulatory subunit, PPP1R15. Two
such regulatory subunits are known: the constitutive repres-
sor of eIF2a phosphorylation (CReP), encoded by PPP1R15B,
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acts under basal conditions (8), while GADD34, encoded by
PPP1R15A, is activated by eIF2a phosphorylation and feeds
back negatively on PERK signaling to promote the recovery
of protein synthesis as the stress response wanes (9). The
PERK pathway and its regulation are especially important for
pancreatic b-cell function and survival (10–12). Homozygous
mutations in EIF2AK3 cause Wolcott-Rallison syndrome,
a syndromic form of neonatal diabetes with epiphyseal
dysplasia, growth retardation, and variable other manifes-
tations including microcephaly (11,13)—features mirrored
in Perk knockout mice (14). Unmitigated ER stress contrib-
utes to b-cell demise in several other monogenic forms of
diabetes. Mutations in the insulin gene that disrupt pro-
insulin folding cause severe b-cell ER stress and neonatal
diabetes (15). The loss of the ER cochaperone p58IPK, due to
DNAJC3 mutations, leads to a syndrome with young-onset
diabetes (16).
Here, we report on a PPP1R15B mutation in two sib-
lings with young-onset diabetes, microcephaly, and short
stature. The mutation, located in the PP1 binding domain
(8), disrupts PP1 binding and eIF2a dephosphorylation
and reveals that b-cell dysfunction and apoptosis may
be caused both by too little and by too much eIF2a phos-
phorylation.
RESEARCH DESIGN AND METHODS
Patients
We studied a consanguineous family of Algerian origin,
with two siblings affected by young-onset diabetes that is
associated with short stature, microcephaly, and intellectual
disability. The study was explained to the patients, their
parents, tutors, and other family members, who agreed
to participate in the genetic study and signed informed
consents. The study protocol was approved by the local
ethics committee. Blood samples were obtained from the
two affected siblings and two nonaffected relatives (the
paternal grandmother and a paternal aunt) and DNA was
extracted using standard procedures.
Exome Sequencing and Analysis
Exome sequencing was performed on the genomic plat-
form of IntegraGen (Evry, France). Exons of genomic DNA
of the index case (patient 1) were captured with in-
solution enrichment methodology (SureSelect Human All
Exon Kits, version 2; Agilent Technologies, Santa Clara, CA)
with the company’s biotinylated oligonucleotide probe li-
brary (Human All Exon, version 2, 50 Mb; Agilent). Geno-
mic DNA was then sequenced on a sequencer as paired-end
75 bases (Illumina HiSeq 2000; Illumina, San Diego, CA).
Image analysis and base calling were performed with Real-
Time Analysis software, version 1.14 with default parame-
ters (Illumina). Bioinformatic analysis was performed by
an in-house pipeline (IntegraGen) based on the Consen-
sus Assessment of Sequence and Variation (CASAVA 1.8;
Illumina) to perform alignment against human reference
genome (GRCh37/hg19), variant calling, and coverage
analysis. The overall sequencing coverage over the whole
exome was 88% and 79% for a 103 and 253 depth of
coverage, respectively, resulting in a mean sequencing
depth of 643 per base. Exome variant analysis was then
performed using an in-house python pipeline on genetic
variation annotation results (M.D., A.P., and C.J., un-
published data). Variants were ﬁltered consecutively
based on their quality, their genotype (homozygous status),
and the predicted consequence on coding capacity (missense,
nonsense, splice-site, and coding insertion/deletion—
inframe or frameshift) and for their rare status based
on information available in in-house (control subjects,
IntegraGen) and public databases (Exome Variant Server
[EVS], ESP6500SI; Exome Aggregation Consortium [ExAC],
release 0.3; and Single Nucleotide Polymorphism database
[dbSNP], version 138). Variants that were homozygous or
had a minor allele frequency .0.005 in any in-house or
public database were excluded.
Variant Conﬁrmation and Test for Diabetes
Segregation in the Family
Each rare variant identiﬁed as homozygous in patient 1
by exome sequencing was conﬁrmed in patient 1 and
further genotyped in patient 2, in two nonaffected relatives
(a paternal grandmother and a paternal aunt), and in an
unrelated healthy control subject. This was done by Sanger
sequencing or by PCR-restriction fragment length poly-
morphism (RFLP) genotyping using speciﬁc ampliﬁcation
primers and restriction enzymes that differentiate the
two alleles, followed by agarose gel electrophoresis using
standard techniques. Sequencing primers and PCR-RFLP
primers/enzymes are available on request.
Sanger Sequencing of PPP1R15B Exons and
Regulatory Regions
Sanger sequencing of PPP1R15B exons (coding, 59UTR and
39UTR regions) and ﬂanking regions of a 680 base pair of
promoter region and a 800 base pair intronic region that
shows species conservation and contains unspliced human
ESTs (UCSC Genome Browser) was performed by BigDye
Terminator sequencing on PCR-ampliﬁed DNA using an
Applied Biosystems 3730 DNA Sequencer (Foster City,
CA). PCR and sequencing primers are shown in Supplemen-
tary Table 1. Sequence interpretation was performed using
the Genalys software (17).
Cell Culture
Clonal rat INS-1E cells (a kind gift from Dr. C. Wollheim,
Centre Médical Universitaire, Geneva, Switzerland) were
cultured in RPMI medium as described (18). Male Wistar
rats (Charles River Laboratories, Châtillon-sur-Chalaronne,
France) were housed and handled following the rules of the
Belgian Regulations for Animal Care. Rat tissues were col-
lected and islets were handpicked under a stereomicroscope
after isolation by collagenase digestion (19). b-Cells were
puriﬁed by autoﬂuorescence-activated cell sorting of
dispersed islet cells (FACS, FACSAria; BD Biosciences,
Erembodegem, Belgium) and cultured as previously de-
scribed (20). Human embryonic kidney (HEK)293T cells
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were maintained in DMEM supplemented with 10% FBS,
100 mU/mL penicillin, 100 mU/mL streptomycin, and
2 mmol/L L-glutamine.
Generation of the R658C Mutant PPP1R15B
Expression Plasmid
The R658C mutation was introduced in the
PPP1R15BpEGFP_C1 plasmid (21) using QuikChange II
Site-Directed Mutagenesis Kit (Agilent) and the primers
huPPP1R15B_R658C_1S: GTGGTGATGAGGATTGCAA
AGGACCATGG and huPPP1R15B_R658C_2AS: CCATG
GTCCTTTGCAATCCTCATCACCAC (bold letters indicate
the mutation site). This vector allows the expression of
recombinant proteins fused to GFP at its N-terminus. Af-
ter mutagenesis, positive clones were sequenced (Seqlab,
Göttingen, Germany), and the following primers were used
to cover the entire gene: F1: CATGGTCCTGCTGGAGTTCGTG,
F2: AGAGGAGGGGATCCACTG, F3: ACAGTGATGGAAA
TAGCGAG, F4: ATCTAGTGAGATACCTATGG, F5: TGA
GACCCCTGAGCATAG, Rev: CACACCTCCCCCTGAAC. Plas-
mids containing the mutation but no other change in the
PPP1R15B gene were introduced into one-shot TOP10
Electrocomp Escherichia coli (Invitrogen, Gent, Belgium)
by electroporation. The cells were recovered for 1 h in
SOC medium, plated on Luria broth agar containing 50
mg/mL kanamycin, and incubated overnight at 37°C. Se-
lected colonies were grown overnight at 37°C on Luria
broth containing 50 mg/mL kanamycin. Plasmids were
puriﬁed using the PureYield Plasmid Midiprep Kit (Prom-
ega, Leiden, the Netherlands) according to the manu-
facturer’s instructions. The DNA concentration was
measured using NanoDrop 3300 (Thermo Scientiﬁc,
Gent, Belgium).
PPP1R15B Overexpression and Immunoprecipitation
HEK293T cells were transfected with EGFP expression
plasmid (pEGFP) without insert (empty vector) or
expressing wild type (WT) or mutant PPP1R15B, alone
or combined with a mouse PP1A expression plasmid
using PEI reagent. After 24 h, the cells were lysed as
previously described (8).
Using 1 mL anti-GFP antibody bound to 15 mL protein
A sepharose resin, GFP-PPP1R15B was puriﬁed from
equal amounts of cell lysate protein. The immunoprecipi-
tates containing PPP1R15B were washed twice in lysis
buffer before being resolved on a 10% SDS-PAGE gel and
blotted onto PVDF (polyvinylidene ﬂuoride) membranes
or used for dephosphorylation studies.
Dephosphorylation Assay
PPP1R15B immunoprecipitates were resuspended in
dephosphorylation buffer containing 50 mmol/L Tris
(pH 7), 100 mmol/L NaCl, 0.1 mmol/L EDTA, 0.1% Triton
X-100, 1 mmol/L DTT, and 1 mmol/L MnCl2 and incubated
with phosphorylated eIF2a for 5–60 min at 30°C. The
supernatant was resolved on 15% phos-tagged SDS-PAGE
gel and visualized using EZBlue gel staining reagent (Sigma-
Aldrich, Dorset, England).
RNA Interference
Clonal and primary rat b-cells were transfected overnight with
30 nmol/L control small interfering RNA (siRNA) (Qiagen,
Germantown, MD) or siRNAs targeting rat PPP1R15B, DP5,
PUMA, or Bim using Lipofectamine RNAiMAX (Invitrogen)
as previously described (22). The siRNAs used in the cur-
rent study are listed in Supplementary Table 2.
Total RNA and mRNA Extraction and Real-Time PCR
Poly(A)+ mRNA and total RNA were isolated and reverse
transcribed as previously described (19,23). Real-time PCR
was performed using Rotor-Gene SYBR Green on a Rotor-
Gene Q cycler (Qiagen) (23,24). Primers were used in a con-
ventional PCR for preparing the standards. Gene expression
was calculated as copies/mL (25). Expression levels were
corrected for expression of the reference gene GAPDH.
Primer sequences are provided in Supplementary Table 3.
Western Blotting
Tissue and cell preparation were performed as previously
described (26). Immunoblotting was done using antibod-
ies against b-actin, phosphorylated eIF2a, eIF2a, BCL-2,
BCL-XL, caspase 9, caspase 3, Cox IV (Cell Signaling, Lei-
den, the Netherlands), human a-tubulin (Sigma-Aldrich),
human ATF3, human PP1 (Santa Cruz, Heidelberg, Ger-
many), cytochrome c (BD Biosciences), or GFP produced
in rabbits. Protein detection was performed using DyLight
conjugated secondary antibody or horseradish peroxidase–
conjugated secondary antibodies and SuperSignal West Femto
chemiluminescence revealing reagent (Thermo Scientiﬁc).
Immunoreactive bands were detected with a ChemiDoc
XRS+ system and with Image Lab software (Bio-Rad,
Hercules, CA). Protein levels were corrected for a-tubulin
or b-actin.
Cell Treatment and Apoptosis Assays
Free fatty acid (FFA) exposure was done in RPMI 1640
medium containing 0.75% FFA-free BSA (Roche, Mannheim,
Germany) and 1% FBS. Oleate and palmitate (Sigma-
Aldrich) were dissolved in 90% ethanol and diluted 1:100 to
a ﬁnal concentration of 0.5 mmol/L (27,28). Cyclopiazonic
acid (CPA) was used at 25 mmol/L, tunicamycin at 5 mg/mL,
and brefeldin A at 0.1mg/mL. The PERK inhibitor GSK2606414
was used at 0.5mmol/L (29). Apoptotic cell death was detected
and counted by ﬂuorescence microscopy after Hoechst
33342 (5 mg/mL; Sigma-Aldrich) and propidium iodide
(5 mg/mL) staining (28,30).
Glucose-Stimulated Insulin Secretion
Insulin secretion was measured as previously described (22).
Brieﬂy, INS-1E cells were washed with modiﬁed Krebs-
Ringer bicarbonate HEPES solution (KRB) and incubated
for 30 min with KRB without glucose, and insulin secretion
was induced by 30-min incubation with KRB containing
1.67 or 16.7 mmol/L glucose with or without 10 mmol/L
forskolin. Insulin was measured by ELISA (Mercodia,
Uppsala, Sweden) in cell-free supernatants and acid-ethanol
extracted cell lysates. Total protein was measured in cell
lysates using the Protein Assay Dye Reagent (Bio-Rad).
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Cytochrome C Release
Cells were harvested in PBS 48 h after transfection. After
centrifugation, a cytosolic lysis buffer containing 0.8 mg/mL
digitonin was added to the pellet. The cells were vortexed for
30 s and centrifuged at 4°C at 20,0003g for 1 min. The
supernatant was separated as cytoplasmic fraction and the
pellet was used as the mitochondrial fraction. Laemmli buffer
was added and the samples were resolved on 12% SDS-PAGE.
Statistical Analysis
Data are presented as means6 SE. Given the paired nature of
the experimental design, comparisons between groups were
made by two-sided Student paired t test, with Bonferroni
correction for multiple comparisons when needed. A P
value ,0.05 was considered statistically signiﬁcant.
RESULTS
Description of a Novel Diabetes Syndrome With
Young-Onset Diabetes, Short Stature, and
Microcephaly
We studied two siblings with young-onset diabetes,
intellectual disability, microcephaly, and short stature who
were born to ﬁrst-cousin consanguineous parents without
diabetes (see Table 1 and Fig. 1 for the description of the
patients). The index case (patient 1), a boy, was diagnosed
with diabetes at age 15 years, with acute onset of polyuria
and polydipsia. Fasting glucose was 13.4 mmol/L and HbA1c
was 13.0% (119 mmol/mol). Type 1 diabetes–speciﬁc auto-
antibodies (islet cell antibody, GAD, IA2 antibodies) were
negative. Fasting C-peptide was low but within normal
range for normoglycemic subjects (Table 1), showing
that at least some residual b-cell mass remained. He
was treated with twice-daily insulin injections. Diabetes
was initially well controlled with relatively low doses of
insulin (;0.5 units/kg/day) but evolved to signiﬁcant glu-
cose variability with severe hypoglycemia episodes and seiz-
ures. He had growth retardation (Fig. 1A), reaching an adult
height of 155 cm, with normal growth hormone (peak at
41 ng/mL after ornithine stimulation test; normal reference
values [N] .10) and IGF1 levels (291 mg/L; N = 249–672).
Thyroxine (18 pmol/L; N = 10–23) and glucagon (116 ng/L;
N = 25–250) levels were normal. Blood cell count, electro-
lytes, creatinine, liver enzymes, bilirubin, cholesterol, trigly-
cerides, lactate, and pyruvate levels were normal. He had
delayed puberty, with an undescended right testis that was
surgically corrected. No anomaly of the gonadal function was
found, with normal levels of testosterone (9.54 nmol/L;
N = 9.0–26.0), luteinizing hormone (4.4 mU/mL; N =
0.24–5.9), and follicle-stimulating hormone (6.5 mU/mL;
N = 1.9–11.6). He had microcephaly (adult cranial perimeter:
46 cm, 24.0 SD) and severe intellectual disability, with
a quiet introverted character. At 15 years of age, his mental
level was comparable to that of a 5- to 6-year-old child.
He answered questions using simple sentences but could
not read or write. His vocabulary was limited to 200–300
words and he did not engage in conversation. He was
able to perform tasks such as feeding, dressing, and bathing
but required full assistance in daily life. MRI showed rare-
faction of the white matter (Fig. 1B), with a nonspeciﬁc
slightly elevated level of protein in the cerebrospinal ﬂuid
(albumin and IgG). He had neurogenic deafness (hearing loss
of 39%). He also had kyphoscoliosis, pectus excavatum, mild
abnormalities of vertebral bodies (Fig. 1C and D), ﬁne ﬁn-
gers and toes, oligodontia and dental hypoplasia, sparse
hair, and a high-pitched voice. Eye fundus was normal.
Clinical and biochemical examination at 28 years of age
showed that his diabetes was relatively well controlled
(Table 1). Glucagon-stimulated C-peptide was detectable.
Table 1—Clinical and biochemical characteristics of the two patients
Patient 1 Patient 2
Sex Male Female
Age at diabetes onset, years 15 28
Age at follow-up examination, years 15* 28 31
Anthropometry
Height, cm (SD) 146 (23.5) 155 (23.2) 139 (24.2)
Weight, kg (SD) 31.4 (23.2) 44.3 (23.5) 30 (24.0)
BMI, kg/m2 (SD) 14.7 (22.7) 18.4 (21.7) 15.5 (22.5)
Microcephaly Yes Yes Yes
Cranial perimeter, cm (SD) 46 (24.0) 46 (24.0) NA
Glucose metabolism
HbA1c, % [N = 4.0–6.0] 13.0 7.8 NA
C-peptide secretion evaluation
Fasting glycemia, mmol/L [N = ,5.6] 3.96 11.4 NA
Fasting C-peptide, nmol/L [N = 0.25–1.28] 0.56 NA NA
Glucagon-stimulated C-peptide, nmol/L [N .0.6] NA 0.89 NA
Therapy
Insulin therapy duration, years 0 13 3
Insulin dose, units/kg/day 0 0.5 0.7
SD is based on French normative values. *, at diabetes onset.
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Pubertal development was fully achieved (Tanner stage 5)
with adult genitalia and complete epiphyseal closure on
bone age X-ray. Biochemical measurements in serum
showed low 25-hydroxyvitamin D (55 nmol/L; N = 75–
340), but normal levels of calcium, IGF-1, and thyroxine.
Markers of phosphate metabolism were normal: parathy-
roid hormone (19 pg/mL; N = 10–55), serum phosphate
(1.54 mmol/L; N = 1.30–1.85), and alkaline phosphatase
(320 units/L; N = 210–830). Urinary calcium-to-creatinine
ratio was also normal (0.33; N ,0.7). His weight and BMI
were low at 44.3 kg and 18.4 kg/m2, respectively. Dual-
energy X-ray absorptiometry showed normal body compo-
sition and bone mineral content. Overall, these results are
in keeping with bone dysplasia without marked distur-
bance of calcium metabolism, with severe growth retarda-
tion unrelated to pituitary or thyroid dysfunction. Serum
amylase, blood cell count, liver and kidney function, and
iron metabolism were normal. On ultrasound, liver and
pancreas were normal, while the kidneys were small,
with mild dilation of right calyces.
Figure 1—Imaging of brain and skeleton of patient 1. A: Growth chart, showing growth retardation. B: Coronal T2-weighted brain MRI at
age 15 years, showing a moderate white matter rarefaction characterized by increased sulcal size and moderate enlargement of ventricular
system. C and D: Skeletal radiographies at age 28 years, showing kyphoscoliosis with tall vertebral bodies and hyperlordosis.
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His sister (patient 2) had a similar clinical presentation,
but she was not available for detailed evaluation. She had
growth retardation, microcephaly, intellectual disability,
and diabetes presenting with an acute onset of hypergly-
cemia and ketosis at age 28 years. She was treated by
insulin. She also had dental hypoplasia, an introverted
character, and high-pitched voice. She had menarche at the
age of 14 years. At the last examination at 31 years of age,
body weight was 30 kg, height 139 cm, BMI 15.5 kg/m2
(Table 1). Blood cell count, electrolytes, and kidney func-
tion parameters were normal. Early clinical history was
unavailable for these patients, except for the information
that they were born small for gestational age. The parents
had normal fasting glucose (father, 5.1 mmol/L; mother,
4.3 mmol/L; N ,5.6), and the mother was not known to
have had gestational diabetes mellitus. They were unavail-
able for further clinical examination and genetic study.
Identiﬁcation of a Homozygous Mutation in the
PPP1R15B Gene in the Two Siblings With Diabetes
Because of the familial context, we hypothesized that the
syndrome was caused by an autosomal recessive mutation.
To test this hypothesis, we performed exome sequencing
on patient 1’s genomic DNA and identiﬁed 18 rare homo-
zygous autosomal variants after ﬁltering (coding variants,
minor allele frequency ,0.005, and absence of subjects
homozygous for the rare variant in public and in-house
databases; Supplementary Tables 4 and 5). We conﬁrmed
these variants in patient 1 and genotyped them in patient
2 and in two nonaffected relatives (a grandmother and an
aunt) by Sanger sequencing or PCR-RFLP genotyping. This
reduced the number of variants to 6, for which both sib-
lings, but not the unaffected relatives, were homozygous
for the rare allele: ADAMTSL4, FLG, KIF21B, PPP1R15B,
and SLC45A3, located on chromosome 1, and UNC80, lo-
cated on chromosome 2 (Supplementary Tables 5 and 6).
Because of the relative similarities of this syndrome with
Wolcott-Rallison syndrome (EIF2AK3 mutations), the fea-
tures of the Ppp1r15b2/2 mouse (very small size at birth
and early death), and its role in the ER stress response
(31), PPP1R15B (Fig. 2A) appeared as the major candidate
(Supplementary Table 6). None of the other genes showed
obvious functional relevance to the syndrome (Supplemen-
tary Table 6). PPP1R15B is ubiquitously expressed (and well
Figure 2—Identiﬁcation of a homozygous PPP1R15B-R658C mutation in two siblings with diabetes and consequences of the mutation on
the protein. A: Sanger sequencing of a control subject and the two siblings with diabetes (ﬁlled symbols), presenting the homozygous
mutation and its consequence on the cDNA and protein. B: PPP1R15B protein sequence, showing the alignment of a highly conserved 62
amino acid segment (hatched) located within the COOH-terminal functional core region (gray). Representative sequences aligned are
PPP1R15B from human (PR15B_HUMAN, Q5SWA1) and mouse (PR15B_MOUSE, Q8BFW3); PPP1R15A from human (PR15A_HUMAN,
O75807), mouse (PR15A_MOUSE, P17564), and drosophila (PR15A_DROME, Q9W1E4); and homologous proteins from a variety of
viruses: African Swine fever virus (VF71_ASFB7, Q65212), Amsacta moorei entomopoxvirus L (NP_064975), Glossina pallidipes salivary
gland hypertrophy virus (YP_001687092), Choristoneura occidentalis granulovirus (YP_654457), and Trichoplusia ni ascovirus 2c
(YP_803309). The mutated arginine (R) at position 658 is part of the functional RVxF-FF-R motif (boxed and underlined on human
PPP1R15B) that has been recognized in PP1-interacting proteins (33). Residues shown in red are fully conserved in selected species;
residues that are the most critical for establishing contact with PP1 according to Chen et al. (32) are indicated by stars.
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expressed in human islets and b-cells), consistent with the
multisystem disease manifestations, while the other genes
have a lower expression in islets and their pattern of tissue
expression does not speciﬁcally correspond to the syn-
drome (Supplementary Fig. 1, Supplementary Table 6).
The R658 residue of PPP1R15B is highly conserved be-
tween organisms, including viruses (Fig. 2B), and the
R658C mutation is predicted to be damaging by in silico
prediction programs (Supplementary Table 6). It is lo-
cated in the conserved COOH-terminal functional core of
PPP1R15B that speciﬁes interaction with PP1, the recruit-
ment of the essential cofactor G-actin, and substrate-speciﬁc
dephosphorylation (21,32). In the cocrystal structure,
PPP1R15B R658 inserts deep into a pocket on the surface
of PP1 (34), giving rise to an ionic interaction with PP1
residue D71 that is conserved in other holophosphatases
such as PP1-PPP1R10 (PNUTS) and PP1-PPP1R9B (spinophilin)
(33). Collectively, these structural observations strongly
support a critical role of R658 in PP1 binding and predict
that the mutation of this residue has deleterious effects
on protein function.
To search for additional patients with PPP1R15B muta-
tions, we performed Sanger sequencing of PPP1R15B
exons, ﬂanking regions, and main regulatory regions (Sup-
plementary Table 1) in 50 patients with a similar clinical
presentation, i.e., insulin-dependent diabetes and short
stature and/or mental retardation or microcephaly, and
in 22 patients with diabetes and their families compat-
ible with monogenic diabetes and linkage to the PPP1R15B
chromosome region (C.J., unpublished data), but we did not
identify any homozygous or compound heterozygous
PPP1R15B mutations in these patients.
R658C Mutation Destabilizes the PPP1R15B-PP1
Complex and Impairs eIF2a Dephosphorylation
To study the effect of the R658C mutation on PPP1R15B
function, we generated a plasmid encoding the fusion
of WT or R658C-mutated human PPP1R15B to EGFP.
HEK293T cells were transfected with either plasmid or
the empty pEGFP vector, alone or in combination with
a plasmid expressing mouse PP1A. The PPP1R15B-PP1
complex was immunoprecipitated from cell lysates using
anti-GFP antibody and analyzed for the presence of PP1 by
Western blot. Fewer PP1 were recovered in complex with
mutant PPP1R15B-EGFP compared with WT. This was true
both when endogenous PP1 was examined (compare lanes
1 and 2, Fig. 3A) and when PP1A was overexpressed (com-
pare lanes 5 and 6, Fig. 3A), demonstrating that the R658C
mutation reduced the ability of PPP1R15B to bind PP1, as
suggested by the structural studies.
Figure 3—The R658C mutation destabilizes the PPP1R15B-PP1 complex and diminishes its phosphatase activity. HEK293T cells were
transfected with an empty vector (GFP) or a GFP-tagged WT or R658C-mutated human PPP1R15B, alone or in combination with a mouse
PP1A expression plasmid. PPP1R15B-PP1 complexes were immunoprecipitated from lysed cells with anti-GFP antibody. A: The recovery of
PP1 in complex with PPP1R15B was examined by Western blotting using anti-PP1 antibody. Immunoprecipitated protein is shown on the left
(IP) and the eluant is shown on the right (input). B: The holophosphatase activity was studied in an eIF2a dephosphorylation assay, incubating
the indicated PPP1R15B-PP1 complexes puriﬁed from cells with in vitro phosphorylated eIF2a (eIF2aP) protein for 30 min and resolving the
phosphorylated and nonphosphorylated eIF2a (eIF2a0) on Phos-tag gels. C: A time course of eIF2a dephosphorylation by WT and R658C-
mutated PPP1R15B and PP1A complexes recovered by immunopuriﬁcation from transfected HEK293T cells. Unphosphorylated eIF2a was
loaded onto lane 1 as a reference. The blots are representative of three or more independent experiments with similar outcomes.
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Next, we examined the dephosphorylation activity
of the immunopuriﬁed PPP1R15B-PP1 holophosphatase
complex. Complexes recovered by immunopuriﬁcation of
GFP-tagged WT PPP1R15B were more active at dephos-
phorylating eIF2a in vitro than complexes constituted of
the R658C mutant (compare lanes 4 and 5, Fig. 3B). These
differences were rendered more conspicuous in a time
course study. Complexes containing WT PPP1R15B sub-
stantially dephosphorylated eIF2a protein by 45 min,
whereas in dephosphorylation reactions carried out with
R658C mutant PPP1R15B, substantial amounts of phos-
phorylated eIF2a remained even at the 60-min time
point (compare lanes 7 and 12, Fig. 3C). Thus, the mis-
sense mutation R658C negatively affects the stability of
the PPP1R15B-PP1 complex and, in turn, its ability to
dephosphorylate eIF2a.
PPP1R15B Expression in b-Cells
In clonal rat INS-1E b-cells, PPP1R15B was induced by
different synthetic ER stressors and the saturated FFA
palmitate (Fig. 4A). This induction was prevented by
a chemical inhibitor of PERK (Fig. 4B), suggesting that,
different from other cell types (8), PPP1R15B expression
in b-cells is controlled by the UPR.
Figure 4—PPP1R15B is induced by ER stress in b-cells in a PERK-dependent manner, and PPP1R15B silencing induces eIF2a phosphor-
ylation and ATF3 in b-cells. A: INS-1E cells were exposed to the chemical ER stressors CPA, tunicamycin (TU), or brefeldin A (BR) or to the
FFAs oleate (OL) or palmitate (PAL) for 24 h (n = 5–6). B: INS-1E cells were exposed or not (CT) to CPA in the presence or absence of the PERK
inhibitor GSK2606414 (PERKi). PPP1R15B mRNA expression was examined by real-time PCR and normalized to the reference gene GAPDH.
C: INS-1E cells were transfected with control siRNA (siCT) or two different siRNAs targeting PPP1R15B (P1R15B1 and P1R15B2). After a 48-h
transfection, the cells were treated for 16 h with CPA, OL, or PAL. PPP1R15B mRNA expression was examined by real-time PCR and
normalized to the reference gene GAPDH (n = 4). eIF2a phosphorylation (P-eIF2a) (D and E) and ATF3 (F and G) expression were examined
by Western blot. D and F are representative images of n = 4. E and G represent densitometric quantiﬁcations of D and F, respectively. P-eIF2a
was corrected for total eIF2a. ATF3 expression was corrected for a-tubulin and expressed as fold of CT. Data are presented as means 6 SE.
*treated vs. control, §DMSO vs. PERKi, #siP1R15B vs. siCT by two-sided Student paired t test. *,§,#P < 0.05; **,##P < 0.01; ***,###P < 0.001.
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PPP1R15B Deﬁciency Increases eIF2a
Phosphorylation in b-Cells
Using RNA interference, PPP1R15B was knocked down
in INS-1E cells, resulting in a 75% inhibition of mRNA
expression (Fig. 4C). Consistent with its previously reported
function of constitutive eIF2a phosphatase (8), basal eIF2a
phosphorylation was increased in PPP1R15B-deﬁcient INS-
1E cells (Fig. 4D and E). PPP1R15B silencing did not further
increase eIF2a phosphorylation induced by the synthetic
ER stressor CPA or palmitate (Fig. 4D and E). Phosphor-
ylated eIF2a levels were higher in PPP1R15B-deﬁcient
cells exposed to the unsaturated FFA oleate that per se
does not induce eIF2a phosphorylation (28,34). ATF3
protein was also induced in PPP1R15B-deﬁcient cells un-
der basal conditions (Fig. 4F and G). Thus, PPP1R15B
silencing increases eIF2a phosphorylation and induces
downstream ATF3 protein expression.
PPP1R15B Silencing Decreases Insulin Content and
Glucose-Stimulated Insulin Release
We next evaluated the effect of PPP1R15B deﬁciency on
b-cell function. PPP1R15B knockdown decreased insulin
content in INS-1E cells by 20% (Fig. 5A). In control siRNA-
transfected b-cells, high glucose exposure (16.7 mmol/L)
increased insulin secretion by 2.8-fold. PPP1R15B-deﬁcient
b-cells showed increased basal insulin secretion and little
or no response to high glucose (Fig. 5B). 16.7 mmol/L
glucose plus forskolin induced insulin secretion by 10-
fold in control siRNA-transfected cells, but only by fourfold
after PPP1R15B silencing (P , 0.05).
PPP1R15B-Deﬁcient b-Cells Are Sensitized to
Apoptosis Through the Proapoptotic BH3-Only
Proteins DP5, PUMA, and Bim
We examined the role of PPP1R15B in b-cell survival.
PPP1R15B silencing in clonal (Fig. 6A and B) and primary
rat b-cells (Fig. 6C) sensitized the cells to apoptosis under
basal conditions and induced up to 20% more apoptosis
following exposure to CPA or the FFAs oleate and palmi-
tate (Fig. 6A–C).
To evaluate whether the intrinsic pathway of apoptosis
was involved, we measured mitochondrial cytochrome c
release to the cytoplasm and cleavage of caspase-9 and -3. In
PPP1R15B-deﬁcient INS-1E cells, cytoplasmic cytochrome c
levels were increased (Fig. 6D) and caspase-9 (Fig. 6E) and -3
(Fig. 6F) were cleaved, demonstrating activation of the in-
trinsic pathway of apoptosis.
We next examined which BCL-2 family members
activate the intrinsic pathway of apoptosis. PPP1R15B
deﬁciency induced mRNA expression of the proapoptotic
proteins DP5 and PUMA (Fig. 6G and H), but it did not
signiﬁcantly affect expression of Bim-S protein (Fig. 6I).
The expression of Bim-L and EL (Supplementary Fig. 2A–
C) and the antiapoptotic proteins BCL-2 and BCL-XL (Sup-
plementary Fig. 2D–F) were not modiﬁed by PPP1R15B
deﬁciency. DP5, PUMA, or Bim silencing partially pro-
tected PPP1R15B-silenced b-cells from apoptosis (Fig.
6J), showing that PPP1R15B deﬁciency induces apopto-
sis through the proapoptotic BH3-only proteins DP5,
PUMA, and Bim.
DISCUSSION
R658C is the ﬁrst reported mutation in PPP1R15B, re-
sponsible for a novel diabetes syndrome with onset in
youth/young adulthood. It affects a key amino acid in
the conserved C-terminus region of the protein that makes
contacts with PP1 that is conserved in other holophosphatase
complexes (32,33). We show that the R658C mutation
destabilizes the complex between PPP1R15B and PP1,
and this, in turn, diminishes eIF2a dephosphorylation.
Furthermore, we show that PPP1R15B silencing alters
b-cell function, inducing higher basal insulin secretion
and reducing high glucose responsiveness, which is com-
patible with a role of PPP1R15B in exocytosis (35). This
is consistent with the observation of residual C-peptide
in the index patient and his moderate insulin require-
ment and frequent hypoglycemic events. PPP1R15B si-
lencing also sensitizes b-cells to apoptosis, both under basal
and ER stress conditions, which was induced via the intrinsic
pathway of apoptosis, as in the case of palmitate-induced
eIF2a phosphorylation (36).
Of note, diabetes manifested relatively late in these
patients (at ages 15 and 28 years). Considering the con-
genital nature of the defect, this suggests the role of
compensatory mechanisms that maintain a sufﬁcient b-cell
function for several years. The acute onset of diabetes
suggests a threshold mechanism(s) by which this delicate
balance is disrupted at some stage, as observed in autoim-
mune type 1 diabetes and other forms of monogenic di-
abetes, leading to hyperglycemia (37).
The syndrome caused by the PPP1R15B-R658C muta-
tion results in multisystem manifestations, affecting
b-cells (diabetes), the nervous system (microcephaly,
Figure 5—Glucose-stimulated insulin secretion is blunted by
PPP1R15B deﬁciency in b-cells. INS-1E cells were transfected
with control siRNA (siCT) or two siRNAs targeting PPP1R15B
(siP1R15B1 and siP1R15B2). After a 48-h transfection, insulin se-
cretion was induced by 1.67 mmol/L or 16.7 mmol/L glucose or
16.7 mmol/L glucose + 10 mmol/L forskolin (16.7+FK). A: Cellular
insulin content corrected for total protein. B: Insulin release as per-
cent of insulin content (n = 5). **P < 0.01, ***P < 0.001 vs. 1.67
mmol/L glucose. #P < 0.05, ##P < 0.01, siP1R15B vs. siCT.
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intellectual disability, and hearing loss), and bone (bone
deformities) and general development. This phenotypic
spectrum has interesting overlap with other mutations af-
fecting the levels of ER stress or the response to it. Hence,
b-cell dysfunction, bone abnormalities, microcephaly, and
intellectual disability are shared with the Wolcott-Rallison
syndrome caused by EIF2AK3 mutations, which lead to
higher levels of ER stress associated with less eIF2a
phosphorylation (11,13,38), and with syndromes caused
by mutations in the ER cochaperone DNAJC3 and in
the immediate early response 3 interacting protein 1
(IER3IP1), which both lead to higher levels of ER stress
with more eIF2a phosphorylation (16,39,40). These com-
monalities likely reﬂect the importance of balanced
ER protein synthesis and folding to the function of
secretory cells, with insulin-producing b-cells, collagen-
producing bone cells, and nerve cells especially vulnerable
to imbalance. In the Wolcott-Rallison syndrome (with de-
creased eIF2a phosphorylation), neonatal diabetes is due
to b-cell loss and C-peptide is undetectable (13), while
DNAJC3, IER3IP1, and PPP1R15B mutations (with in-
creased eIF2a phosphorylation) lead to permanent neo-
natal or young-onset diabetes with residual C-peptide
levels, as reported by Synofzik et al. (16), Shalev et al.
(40), and the current study. It is notable that the muta-
tions affecting the target of phosphorylated eIF2a, the
guanine nucleotide exchange factor eIF2B, feature prom-
inent neurodegenerative manifestations known as the
CACH (childhood ataxia with central nervous system
hypomyelination)/VWM (vanishing white matter disease)
Figure 6—PPP1R15B deﬁciency sensitizes b-cells to FFA- and ER stress–induced apoptosis and activates the intrinsic pathway of
apoptosis via DP5, PUMA, and Bim-S. INS-1E (A and B) or primary rat b-cells (C) were transfected with a control siRNA (siCT) or two
different siRNAs targeting PPP1R15B (siP1R15B1 and siP1R15B2). After a 24-h transfection, the cells were exposed or not (CT) to CPA,
oleate (OL), or palmitate (PAL) for 16 (A and B) or 24 h (C) (n = 4–5). D: Mitochondrial cytochrome c (Cyto C) release was detected by
Western blot in the cytoplasmic fraction 48 h after PPP1R15B knockdown. The right lane shows a noncytoplasmic fraction that includes
mitochondria (Mito). Cox IV was used as a mitochondrial control and b-actin as a cytoplasmic control. Activation of caspase-9 (Casp9) (E )
and caspase-3 (Casp3) (F ) was detected by Western blot 48 h after PPP1R15B knockdown. b-Actin and a-tubulin were used as loading
controls. D, E, and F are representative blots of 4–5 experiments. The densitometry data were normalized to the highest value. DP5 (G) and
PUMA (H) mRNA expression were measured by real-time PCR and corrected for the reference gene GAPDH (n = 4). Bim-S levels were
measured by Western blot (Supplementary Fig. 2), corrected for a-tubulin, and expressed as fold of siCT (I) (n = 5). J: PPP1R15B was
silenced alone or in combination with DP5, PUMA, or Bim, and apoptosis was examined by Hoechst 33342/propidium iodide staining (n =
3–4). *P < 0.05, **P < 0.01, ***P < 0.001, treated vs. control. #P < 0.05, ##P < 0.01, ###P < 0.001, siP1R15B vs. siCT. §P < 0.05, single
vs. double knockdown.
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syndrome (41), which are phenocopied by targeted
activation of the eIF2a kinase PERK in the brain (42).
Interestingly, severe forms of CACH/VWM also have
multiorgan manifestations (41,43). The clinical variability
of syndromes associated with dysregulated eIF2a phos-
phorylation likely results from the interplay of several
factors, including the extent of apoptosis and/or secretory
dysfunction resulting from speciﬁc genes mutations,
the severity of the mutation, and possibly environmental
stresses.
The clinical features of PPP1R15B-mutated patients
described here and the phenotype of knockout mice
that we described previously (31) suggest that PPP1R15B
deﬁciency affects multiple cell types. The role of PPP1R15B
in exocytosis and membrane trafﬁc has been previously
reported in human epithelial cells and erythroleukemia
cells (35). The knockdown of PPP1R15B in breast cancer
cells resulted in impaired cell cycle transition from G1 to S
phase and apoptosis (44). These observations suggest that
PPP1R15B regulates a variety of functions in different cell
types. More studies are needed to explore this further.
Although we selected PPP1R15B as an obvious candi-
date gene and found ample structural and functional ex-
perimental support for the impact of the mutation, we
cannot formally exclude that one of the rare variants
homozygous in the two affected siblings contributes to
the syndrome. This hypothesis is unlikely based on the
following reasons (Supplementary Table 6 and Supple-
mentary Fig. 1): 1) none of the other genes appear directly
functionally relevant to the clinical presentation; 2) the
expression pattern of PPP1R15B, but not of the ﬁve other
genes, is consistent with the multisystem presentation of
the syndrome; 3) mutations in ADAMTSL4 cause ectopia
lentis and mutations in FLG cause atopic dermatitis and
ichtyosis vulgaris, and none of these diseases were pres-
ent in the two affected siblings; and 4) human or mouse
disease phenotypes of KIF21B, SLC45A3, and UNC80
mutations have not been reported so far, and a cellular
phenotype of chromosome instability has been reported
in Kif21b2/2 mice, which was not observed in our
patients. In short, the characteristics of these ﬁve other
genes show little relevance to the diabetes and neurolog-
ical phenotype of our patients.
The present human genetic observations are in keeping
with our earlier ﬁndings that excessive eIF2a phosphor-
ylation is poorly tolerated by b-cells. Salubrinal, a chemical
inhibitor of eIF2a dephosphorylation, was identiﬁed in
a large-scale chemical screening as a compound that pro-
tects from ER stress (45), and it was even suggested as
a potential therapy to preserve b-cells in diabetes (46). In
rodent and human b-cells, however, salubrinal actually
exacerbates cell death through ER stress and downstream
activation of the mitochondrial pathway of apoptosis
(10,24). The present observations support the concept
that dysregulation of eIF2a phosphorylation, either ex-
cessive (PPP1R15B, DNAJC3, and IER3IP1 mutations) or
diminished (EIF2AK3 mutations), is detrimental to b-cells,
neurons, and bone and suggest that other proteins in-
volved in the regulation of protein translation may lead
to similar diabetes syndromes.
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